BioQuest Corp.

As of July 31, 2022, BioQuest Corp. carries a market capitalization of 10.80M, placing it among publicly traded companies globally. Its enterprise value stands at 10.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2022, BioQuest Corp. has 11.49M shares outstanding.

These figures are as of July 31, 2022.

As of July 31, 2022, BioQuest Corp. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -34.17, indicating conservative leverage, while an interest coverage ratio of -7.06 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended July 31, 2022. Return on assets (ROA) is negative at -3,483.85, reflecting losses generated across the asset base.

As of the close on October 14, 2026, BioQuest Corp.'s stock has declined approximately 75.00% over the past 52 weeks.

Over the twelve months ended July 31, 2022, BioQuest Corp. generated - - in revenue and converted that into -507,406.00 in net income, yielding earnings per share of -0.05. EBITDA reached -403,445.00, while operating income came in at -403,445.00.

As of July 31, 2022, BioQuest Corp. holds 14,955.00 in cash and equivalents against 183,300.00 in total debt, resulting in a net debt position of 168,345.00. Total book value stands at -536,419.00, with working capital of -536,419.00 providing operational flexibility.

BioQuest Corp. produced -72,781.00 in operating cash flow over the twelve months ended July 31, 2022.

These figures cover the twelve months ended July 31, 2022. Free cash flow yield is negative at -0.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.79, meaning BioQuest Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioQuest Corp.'s most recent stock split took place on November 15, 2019.

As of July 31, 2022, BioQuest Corp. has an Altman Z-Score of -1,130.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.